| Literature DB >> 33083058 |
Wenhan Wu1, Jianbo Liu1, Zongguang Zhou1.
Abstract
OBJECTIVE: Our objective was to comprehensively present the evidence of preoperative risk factors for short-term postoperative mortality of acute mesenteric ischemia after laparotomy.Entities:
Year: 2020 PMID: 33083058 PMCID: PMC7556094 DOI: 10.1155/2020/1382475
Source DB: PubMed Journal: Emerg Med Int ISSN: 2090-2840 Impact factor: 1.112
Figure 1PRISMA flow diagram.
Characteristics of studies.
| Study | Size, no. | Endpoint | Mortality (%) | NOS score |
|---|---|---|---|---|
| Kougias et al., 2007, USA | 72 | 30-day mortality | 31.9 | 7 |
| Crawford et al., 2016, USA | 2255 | Hospital mortality | 24.4 | 6 |
| Alhan et al., 2012, Turkey | 107 | Hospital mortality | 55.1 | 7 |
| Matthaei et al., 2019, Germany | 48 | 30-day mortality | 18.8 | 8 |
| Edwards et al., 2003, USA | 77 | Hospital mortality | 62.3 | 6 |
| Arnalich et al., 2010, Spain | 99 | 30-day mortality | 46.6 | 7 |
| Huang et al., 2005, China | 124 | Hospital mortality | 50.0 | 7 |
| Park et al., 2002, USA | 58 | 30-day mortality | 32.8 | 7 |
| Acosta-Merida et al., 2006, Spain | 132 | Hospital mortality | 65.2 | 8 |
| Hsu et al., 2006, China | 77 | 30-day mortality | 53.2 | 6 |
| Gupta et al., 2011, USA | 861 | 30-day mortality | 27.9 | 6 |
| Yılmaz et al., 2017, Turkey | 34 | Hospital mortality | 44.1 | 7 |
| Aliosmanoglu et al., 2013, Turkey | 95 | Hospital mortality | 42.1 | 8 |
| Marchena-Gomez et al., 2009, Spain | 186 | Hospital mortality | 64.5 | 6 |
| Groteluschen et al., 2019, Germany | 302 | Hospital mortality | 67.8 | 7 |
| Vural et al., 2019, Turkey | 37 | 30-day mortality | 24.3 | 6 |
| Akyildiz et al., 2015, Turkey | 104 | 30-day mortality | 66.3 | 7 |
| Merle et al., 2004, France | 103 | 72-hour mortality | 29.1 | 7 |
| Studer et al., 2015, Switzerland | 91 | Hospital mortality | 42.9 | 7 |
| Paladino et al., 2014, Italy | 149 | Hospital mortality | 38.3 | 7 |
NOS, Newcastle-Ottawa Scale.
Association between clinical characteristics and short-term postoperative mortality.
| Factor | Number of studies | Number of patients | OR (95% CI) (nonsurvivors: survivors) or standardized mean difference (nonsurvivors-survivors) of factor |
| Heterogeneity ( |
|---|---|---|---|---|---|
| Demographic | |||||
| Age | 8 | 2900 | 0.32 (0.24–0.40) | <0.0001 | 0.00 |
| Old age | 4 | 2502 | 1.90 (1.57–2.30) | <0.0001 | 0.00 |
| Male sex | 11 | 3126 | 1.03 (0.87–1.21) | 0.75 | 4.46 |
|
| |||||
| Comorbidities | |||||
| Coronary heart disease | 6 | 2782 | 1.14 (0.70–1.88) | 0.59 | 59.24 |
| Atrial fibrillation | 4 | 581 | 1.42 (0.79–2.55) | 0.24 | 52.01 |
| Heart failure | 4 | 2534 | 1.33 (1.03–1.72) | 0.03 | 0.00 |
| Hypertension | 6 | 2866 | 1.19 (0.57–2.48) | 0.64 | 87.56 |
| Atherosclerosis | 2 | 393 | 0.84 (0.54–1.30) | 0.43 | 0.00 |
| Arrhythmia | 2 | 2379 | 1.62 (1.33–1.98) | <0.0001 | 0.00 |
| Previous cardiac disease | 3 | 326 | 1.80 (0.86–3.73) | 0.12 | 55.84 |
| Diabetes | 9 | 3307 | 1.51 (0.97–2.36) | 0.07 | 65.92 |
| Chronic lung disease | 3 | 2453 | 1.34 (1.04–1.73) | 0.02 | 0.00 |
| Renal disorders | 5 | 2683 | 1.61 (1.24–2.07) | 0.0003 | 14.33 |
| Peripheral vascular diseases | 5 | 2641 | 1.38 (1.00–1.91) | 0.05 | 0.00 |
| Comorbidity | 2 | 199 | 3.49 (1.88–6.46) | <0.0001 | 0.00 |
|
| |||||
| Etiology | |||||
| AOMI vs MVT | 4 | 379 | 2.45 (1.12–5.33) | 0.04 | 11.10 |
| NOMI versus AOMI | 5 | 486 | 1.33 (0.56–3.16) | 0.52 | 56.86 |
| NOMI versus MVT | 4 | 379 | 2.50 (0.79–7.93) | 0.12 | 27.23 |
|
| |||||
| Medications history | |||||
| Antiplatelet | 5 | 764 | 2.23 (0.77–6.44) | 0.14 | 81.15 |
| Anticoagulant therapy | 3 | 525 | 0.59 (0.19–1.79) | 0.35 | 65.48 |
| Digoxin | 2 | 239 | 3.77 (2.02–7.02) | <0.0001 | 0.00 |
|
| |||||
| Initial clinical symptoms | |||||
| Abdominal pain | 4 | 462 | 0.71 (0.18–2.81) | 0.63 | 74.02 |
| Abdominal distension | 2 | 231 | 1.43 (0.76–2.68) | 0.27 | 0.00 |
| Diarrhea | 2 | 231 | 0.62 (0.31–1.27) | 0.19 | 0.00 |
| Vomiting | 2 | 231 | 0.59 (0.35–0.99) | 0.05 | 0.00 |
|
| |||||
| Physical findings | |||||
| Fever | 2 | 239 | 0.96 (0.44–2.07) | 0.91 | 0.00 |
| Body temperature | 2 | 231 | 0 (−0.26–0.25) | 0.99 | 0.00 |
| Pulse rate | 2 | 231 | 0.42 (0.16–0.68) | 0.002 | 6.58 |
| Blood pressure | 2 | 231 | −1.00 (−2.18–0.18) | 0.1 | 94.38 |
| Hypotension after admission | 2 | 227 | 2.86 (1.39–5.91) | 0.005 | 0.00 |
| peritonitis | 2 | 210 | 1.72 (0.93–3.17) | 0.08 | 0.00 |
| Sepsis | 2 | 227 | 2.10 (1.16–3.80) | 0.01 | 0.00 |
| Shock | 2 | 239 | 4.18 (1.99–8.78) | 0.0002 | 0.00 |
|
| |||||
| Computed tomography findings | |||||
| Bowel-wall thickening | 2 | 426 | 0.49 (0.24–0.99) | 0.05 | 33.45 |
| Intramural pneumatosis | 2 | 426 | 3.87 (0.23–63.98) | 0.35 | 84.90 |
|
| |||||
| Laboratory tests | |||||
| White blood cell | 7 | 917 | 0.04 (−0.46–0.53) | 0.89 | 91.47 |
| Platelet | 4 | 566 | −0.32 (−0.50 to −0.14) | 0.0004 | 0.00 |
| Hemoglobin | 3 | 541 | −0.16 (−0.46–0.14) | 0.29 | 60.29 |
| Amylase | 3 | 342 | 1.24 (−0.22–2.70) | 0.1 | 96.98 |
| AST | 2 | 405 | 0.60 (0.10–1.10) | 0.02 | 74.99 |
| CPK | 3 | 541 | 0.59 (0.00–1.17) | 0.05 | 89.02 |
| Lactate | 2 | 405 | 0.85 (0.58–1.12) | <0.0001 | 25.49 |
| PH | 3 | 541 | −1.11 (−1.67 to −0.55) | <0.0001 | 86.89 |
| BUN | 2 | 231 | 0.93 (0.11–1.75) | 0.03 | 88.69 |
| Creatinine | 5 | 768 | 0.50 (0.25–0.75) | <0.0001 | 60.38 |
| Bicarbonate | 2 | 239 | −2.34 (−5.78 to 1.09) | 0.18 | 98.77 |
| Bilirubin | 2 | 405 | 0.12 (−0.09 to 0.33) | 0.26 | 0.00 |
| CRP | 2 | 339 | 0.29 (0.05–0.52) | 0.02 | 0.00 |
| CRP ≥ 100 mg/L | 2 | 350 | 0.46 (0.29–0.75) | 0.002 | 0.00 |
Continuous variables compared by standardized mean difference. A negative value indicates mean value was lower in nonsurvivors than survivors. AST: aspartate aminotransferase; AOMI: arterial occlusive mesenteric ischemia; BUN: blood urea nitrogen; CPK: creatine phosphokinase; CRP: C-reactive protein; MVT: mesenteric venous thrombosis; NOMI: nonocclusive mesenteric ischemia.
Summary of risk factors analyzed in multivariate models.
| Risk factors | Study | OR (95% CI) |
|
|---|---|---|---|
| Patient factors | |||
| Age > 60 years | Park et al., 2002 | 3.0 (1.3–6.9) | 0.0093 |
| Age > 65 years | Crawford et al., 2016 | 1.8 (1.4–2.3) | <0.0001 |
| Age > 65 years | Huang et al., 2005 | 1.08 (1.01–1.15) | 0.02 |
| Age > 70 years | Kougias et al., 2007 | 3.6 (1.2–4.2) | 0.03 |
| Age (for each increase of 1 year) | Gupta et al., 2011 | 1.04 (1.02–1.06) | <0.05 |
| Age (for each increase of 1 year) | Marchena-Gomez et al., 2009 | 1.034 (1.003–1.066) | 0.031 |
| Age (for each increase of 1 year) | Vural et al., 2019 | 1.14 (1.005–1.303) | <0.02 |
| ASA class 1 | Gupta et al., 2011 | 0.04 (0.004–0.35) | <0.05 |
| ASA class 2 | Gupta et al., 2011 | 0.15 (0.06–0.37) | <0.05 |
| ASA class 3 | Gupta et al., 2011 | 0.27 (0.13–0.57) | <0.05 |
| ASA class 4 | Gupta et al., 2011 | 0.40 (0.19–0.84) | <0.05 |
| Cardiac dysrhythmia | Crawford et al., 2016 | 1.5 (1.1–1.9) | 0.003 |
| Cardiac illness | Acosta-Merida et al., 2006 | 2.60 (1.02–6.62) | 0.045 |
| Chronic kidney disease | Crawford et al., 2016 | 1.8 (1.4–2.3) | <0.0001 |
| Heart failure | Merle et al., 2004 | 5.9 (1.1–31.8) | 0.029 |
| Hypercoagulability | Crawford et al., 2016 | 2.6 (1.8–3.7) | <0.0001 |
| Metabolic acidosis | Huang et al., 2005 | 6.604 (1.804–24.171) | 0.01 |
| NOMI versus MVT | Hsu et al., 2006 | 12.367 (1.450–105.455) | 0.021 |
| Peritonitis | Edwards et al., 2003 | 22.9 (2.3–225.2) | 0.007 |
| Preoperative hypotension | Edwards et al., 2003 | 14.9 (1.4–160.6) | 0.026 |
| Previous surgery | Park et al., 2002 | 2.4 (1.2–4.9) | 0.0229 |
| Prolonged symptoms duration | Kougias et al., 2007 | 4.6 (1.3–5.1) | 0.02 |
| Sepsis | Gupta et al., 2011 | 3.02 (1.33–6.84) | <0.05 |
|
| |||
| Perioperative factors | |||
| Abnormal albumin | Gupta et al., 2011 | 2.71 (1.32–5.57) | <0.05 |
| AST >200 IU/L | Merle et al., 2004 | 8.5 (1.7–41.9) | <0.001 |
| Bandemia | Huang et al., 2005 | 3.894 (1.160–13.074) | 0.03 |
| Blood hemoglobin (for each increase of 1 g/dl) | Arnalich et al., 2010 | 0.24 (0.10–0.40) | 0.001 |
| BUN (for each increase of 1 mg/dl) | Huang et al., 2005 | 7.219 (1.166–44.696) | 0.03 |
| Creatinine (for each increase of 1 mg/dl) | Marchena-Gomez et al., 2009 | 2.137 (1.3–3.6) | 0.003 |
| Creatinine level ≥ 2 mg/dl | Akyildiz et al., 2015 | 2.4 | 0.04 |
| CRP > 100 mg/L | Groteluschen et al., 2019 | 1.758 (1.012–3.054) | <0.001 |
| Elevated AST | Huang et al., 2005 | 4.532 (1.274–16.122) | 0.02 |
| Glucose (for each increase of 1 mmol/l) | Arnalich et al., 2010 | 1.030 (1.01–1.25) | 0.001 |
| Lactate > 3 mmol/L | Groteluschen et al., 2019 | 2.717 (1.561–4.729) | <0.001 |
| Lactate > 5 mmol/L | Merle et al., 2004 | 5.5 (1.2–24.5) | 0.014 |
| PCT > 40 ng/L | Merle et al., 2004 | 7.4 (1.3–39.2) | 0.006 |
| Urea levels (for each increase of 1 mmol/l) | Acosta-Merida et al., 2006 | 33.89 (5.07–226.51) | <0.001 |
ASA class 5. ASA, American Society of Anesthesiologists Physical Status Classification; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CRP, C-reactive protein; MVT, mesenteric venous thrombosis; NOMI, nonocclusive mesenteric ischemia; PCT, procalcitonin.
Figure 2Forest plots for significant preoperative risk factors for short-term postoperative mortality of AMI after laparotomy with data available in at least four studies (demographics and etiology). AOMI: arterial occlusive mesenteric ischemia; FE: fixed effect; MVT: mesenteric venous thrombosis; RE: random effect. (a) Old age (categorical variable), (b) age (continuous variable), and (c) AOMI versus MVT (categorical variable).
Figure 3Forest plots for significant preoperative risk factors for short-term postoperative mortality of AMI after laparotomy with data available in at least four studies (comorbidities). Notes: renal disorders include renal failure and chronic renal disease. FE: fixed effect; RE: random effect. (a) Heart failure (categorical variable), (b) renal disorders (categorical variable), and (c) peripheral vascular disease (categorical variable).
Figure 4Forest plots for significant preoperative risk factors for short-term postoperative mortality of AMI after laparotomy with data available in at least four studies (laboratory tests). FE: fixed effect; RE: random effect. (a) Creatinine (continuous variable) and (b) platelet (continuous variable).
Summary finds of preoperative risk factors eligible for meta-analysis.
| Risk factor | Number of patients/studies | Regarded as a risk factor | Pooled odds ratio/standardized mean difference | Heterogeneity ( | Quality of evidence (GRADE) |
|---|---|---|---|---|---|
| Advanced age | 2502/4 | Yes | 1.90 (1.57–2.30) | 0 | Low |
| Age | 2751/7 | Yes | 0.31 (0.22–0.40) | 0 | Low |
| AOMI versus MVT | 379/4 | Yes | 2.45 (1.12–5.33) | 11.1 | Moderate |
| Heart failure | 2534/4 | Yes | 1.33 (1.03–1.72) | 0 | Low |
| Renal disorders | 2534/4 | Yes | 1.93 (1.03–3.62) | 35.74 | Low |
| Peripheral vascular disease | 2641/5 | Yes | 1.38 (1.00–1.91) | 0 | Low |
| Creatinine | 768/5 | Yes | 0.50 (0.25–0.75) | 60.38 | Moderate |
| Platelet | 566/4 | Yes | −0.32 (−0.50 to −0.14) | 0 | Low |
Continuous variables compared by standardized mean difference. A negative value indicates mean value was lower in nonsurvivors than survivors. Abbreviations: AOMI: arterial occlusive mesenteric ischemia. Notes: MVT, mesenteric venous thrombosis.